Because they're looking at the long term I suspect and when M7T continues to sell on a capital model it doesn't get them any closer to being consistently cash flow positive or profitable. I disagree that it's a competitive advantage being able to offer flexible contracting, I think it's a sign of weakness that customers have the power to dictate the terms.
Ann: Mach7 signs A$3.1M, 3-year renewal with Penn State Health, page-7
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.015(3.70%) |
Mkt cap ! $91.63M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 40.0¢ | 38.5¢ | $75.91K | 192.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 41935 | 38.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.0¢ | 74693 | 2 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| M7T (ASX) Chart |